Despite the UK being home to one of the world's most dominant financial centres, it ranks only 13th in the OECD in terms of the number of scale-up businesses based in the country.
Put another way, fewer than one in ten firms that receive seed funding in the UK go on to get fourth round investment, compared to nearly a quarter in the US. In order to strengthen the UK as a place where innovative firms can obtain the long-term 'patient' finance they need to scale up, Prime Minister Theresa May announced in November 2016 that HM Treasury would be conducting a Patient Capital Review (PCR). The final recommendations of the PCR will be presented to the Chancellor Philip Hammond ahead of the Autumn Budget and are set to identify the barriers to growing firms accessi...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
